The results showed that Cbp/p300-interacting transactivator 2, tyrosine-protein phosphatase non-receptor type 2, WT1, and 22 other target genes were involved in the occurrence and development of CML. The gene discussed is WT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.